bearish
I-Mab to Divest Chinese Assets and Business Operations for up to $80M - An Escape by Crafty Scheme
507 Views14 Feb 2024 00:55
The divesture means I-MAB US has been "hollowed out",which is a big blow to investors.I-MAB Hangzhou is able to tell more good stories with its pipeline, but I-MAB US may start to decline from here on
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »- I-Mab to Divest Chinese Assets and Business Operations for up to $80M - An Escape by Crafty Scheme
- Quick Ideas #6
- I-Mab (IMAB.US) - An "Entertaining Bet": To Be a Dark Horse or to Fail Completely
- I-Mab BioPharma (IMAB US) – Ph2 Data of Lemzoparlimab (CD47) In 1L MDS Released
- I-Mab BioPharma (IMAB US) – Strong Cash Balance to Fund Business Operations
Trending Collections
More »Trending Insights
More »- Yuanta/P-Shares Taiwan Div+ ETF Rebalance: Huge Turnover & Flow Overlap
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- Merger Arb Mondays (09 June) - Mayne, Tam Jai, OneConnect, Toyota Industries, Makino, Fuji Corp
- [Japan M&A] Private Co Takeout of Fuji Corp (7605 JP) - A Done Deal
- Ohayo Japan | Stocks up on Jobs Data
Top Unpaywalled Insights
More »- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
- [IO Technicals 2025/22] Bearish Momentum Strengthens
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- I-Mab to Divest Chinese Assets and Business Operations for up to $80M - An Escape by Crafty Scheme14 Feb 2024
- China Traditional Chinese Medicine (570.HK) - Will This Privatization Rumor Come True ?08 Feb 2024
- Latest Impact of the US Biosecure Act on WuXi AppTec/WuXi Bio/WuXi XDC - China CXO Really Game Over?05 Feb 2024
- I-Mab (IMAB.US) - An "Entertaining Bet": To Be a Dark Horse or to Fail Completely01 Feb 2023
x